Post-heart attack, patients with lower kidney function not taking prescribed meds

(Press-News.org) Among older adults with a recent heart attack (myocardial infarction), those with lower levels of kidney function are less likely to take their medications as prescribed, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

"Several types of medications have proven benefit for preventing recurrent heart attacks, yet only about half of people with heart disease take their medications correctly," comments Wolfgang C. Winkelmayer, MD, ScD (Stanford University School of Medicine, Palo Alto, CA). "Adherence was lower in patients with more pronounced kidney dysfunction."

The researchers studied 2,103 patients aged 65 or older with a recent heart attack. Pharmacy insurance claims records were used to determine the percentage of days that patients actually had their prescribed medications.

The results showed low long-term adherence rates for three major classes of heart medications: angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEIs/ARBs), beta-blockers, and statin drugs. Over three years' follow-up, the patients had their prescribed drugs for only 50 to 60 percent of the time.

For ACEIs/ARBs and beta-blockers, medication adherence was significantly lower for patients who had lower levels of kidney function at the beginning of the study. Adherence to statin drugs was not significantly related to kidney function.

"Since poor medication adherence increases the risk of hospitalization and death, it is important to understand the scope of the problem," Winkelmayer explains. In a previous study in the same group of patients, the researchers found low medication adherence rates within the first 90 days after heart attack. "In the current study, we wanted to extend these findings to examine long-term outpatient medication adherence, particularly in patients with kidney dysfunction, who are at high risk for recurrent heart attacks but who have not been studied extensively to date." "Future strategies to improve medication adherence and clinical outcomes will need to pay special attention to this high-risk population."

The study had some important limitations. Kidney function was measured based on a single lab test performed in the hospital, which may underestimate the true baseline kidney function. The study included a sample of elderly, low-income patients with a high proportion of whites and women, so the results may not be applicable to a more diverse population. Also, since medication adherence was measured using insurance claims data, the researchers were unable to determine why patients weren't following their prescriptions. "For example, the medication may have been purposely discontinued by the treating physician due to unwanted side effects," says Winkelmayer.



INFORMATION:

Study co-authors were Tara I. Chang, Manisha Desai (both of Stanford University) and Daniel H. Solomon (Harvard Medical School, Boston, MA). The authors reported no financial disclosures.

The article, entitled "Kidney Function and Long-Term Medication Adherence after Myocardial Infarction in the Elderly" (doi 10.2215/CJN.07290810), will appear online at http://cjasn.asnjournals.org/ on January 13, 2011.

The American Society of Nephrology (ASN) does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966 and comprised of more than 12,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.